Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | SI | P14410 | 2/20 | 0.52 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM6B | O15054 | 1/20 | 0.32 |
| ▸ | KDM5C | P41229 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27741667 | 0.80 | MGAM (0.48) | MGAMGAASIMGAM2KDM4E | |
| SCHEMBL10001051 | 0.79 | MGAM (0.67) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL651636 | 0.79 | — | — | |
| SCHEMBL15745840 | 0.79 | MGAM (0.57) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL28295747 | 0.78 | MGAM (0.46) | MGAMGAASIMGAM2KDM4E | |
| SCHEMBL13482020 | 0.77 | ALDH1A1 (0.43) | GAATSHRLMNAALDH1A1HSD17B10 | |
| SCHEMBL2759397 | 0.77 | MGAM (0.62) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL626926 | 0.75 | — | — | |
| SCHEMBL14022135 | 0.75 | MGAM (0.52) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL28694750 | 0.74 | FAAH (0.43) | MGAMGAASIMGAM2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160801-A1 | Pyrimidinone derivaties as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160801-A1 | Pyrimidinone derivaties as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | PTGIS, PTGIR, FPR1 | MGAM 4680/4885GAA 3327/4885SI 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.